Cantrak
Bangrak, Bangkok, Bangkok, Bangrak, 10500, Thailand
Overview
Provides software for the agrifood industry to track and reduce emissions. It optimizes operations for cannabis & hemp businesses with inventory management, cultivation planning, and quality standards for medical-grade products.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 2
- Active investors
- 0
Sector focus
- Software
Investment portfolio
- Womed
Participated · Equity · Jul 2026
Founded in 2018 and based on the CNRS campus in Montpellier, Womed develops intravaginal/intrauterine polymer-based treatments for women's health. Its FDA-approved device Womed Leaf is intended to prevent intrauterine adhesions and the company reports about 2,000 women helped to date with a target of 95,000 women treated per year by 2028. Eynia is an investigational, gynecologist-administered biodegradable polymer treatment for fibroids that blocks progesterone for three months before degrading, and is planned to enter phase II trials. Womed says it aims to expand into treatments for acute bleeding and endometriosis. The company employs ten people and works with a similar number of consultants, including Dr André Ulmann. Financially, Womed recently raised €5 million from institutional investors, is running €1 million in public crowdfunding, and had previously raised €6 million in 2024.
- Plasana Medical
Participated · Equity · Oct 2025
Plasana Medical, born out of the Laboratoire de physique des plasmas of École polytechnique and the CNRS, is building Plasana One, a proprietary multi-jet cold-plasma device designed to stimulate tissue regeneration while limiting infection risk in chronic wounds such as diabetic foot ulcers, venous ulcers and pressure sores. The treatment is positioned to be six-to-twelve times faster and painless, targeting a 30–50 % reduction in healing time and enabling home-care use for the roughly 10 million patients affected in Europe and the United States. Backed by more than ten years of academic research and support from TechnoFounders, the company plans to complete its first French clinical trial (Plasana Genesis) and secure CE marking by 2026, followed by U.S. market entry. Commercial launch of its first product is expected within two years. Financially, Plasana has just secured €4 million in mixed financing (equity, grants and bank loans) to fund these milestones. No revenue or user metrics have been disclosed to date, and the company remains pre-commercial with its focus on product validation and regulatory clearance.
Team
No current team members are available.